BR9809304B1 - formulação liofilizada estável, processo para preparação da mesma, bem como forma de dosagem unitária. - Google Patents

formulação liofilizada estável, processo para preparação da mesma, bem como forma de dosagem unitária. Download PDF

Info

Publication number
BR9809304B1
BR9809304B1 BRPI9809304-5A BR9809304A BR9809304B1 BR 9809304 B1 BR9809304 B1 BR 9809304B1 BR 9809304 A BR9809304 A BR 9809304A BR 9809304 B1 BR9809304 B1 BR 9809304B1
Authority
BR
Brazil
Prior art keywords
formulation
apc
sucrose
activated protein
protein
Prior art date
Application number
BRPI9809304-5A
Other languages
English (en)
Portuguese (pt)
Other versions
BR9809304A (pt
Inventor
Andrew David Carlson
Theodore Arsay Sheliga
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of BR9809304A publication Critical patent/BR9809304A/pt
Publication of BR9809304B1 publication Critical patent/BR9809304B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BRPI9809304-5A 1997-04-28 1998-04-24 formulação liofilizada estável, processo para preparação da mesma, bem como forma de dosagem unitária. BR9809304B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4525597P 1997-04-28 1997-04-28
US60/045,255 1997-04-28
PCT/US1998/008386 WO1998048818A1 (en) 1997-04-28 1998-04-24 Activated protein c formulations

Publications (2)

Publication Number Publication Date
BR9809304A BR9809304A (pt) 2000-10-17
BR9809304B1 true BR9809304B1 (pt) 2011-02-08

Family

ID=21936854

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI9809304-5A BR9809304B1 (pt) 1997-04-28 1998-04-24 formulação liofilizada estável, processo para preparação da mesma, bem como forma de dosagem unitária.
BR9809292-8A BR9809292A (pt) 1997-04-28 1998-04-24 Métodos aperfeiçoados para o processamento de proteìna c ativada

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR9809292-8A BR9809292A (pt) 1997-04-28 1998-04-24 Métodos aperfeiçoados para o processamento de proteìna c ativada

Country Status (34)

Country Link
US (4) US6162629A (cg-RX-API-DMAC7.html)
EP (2) EP0875563A3 (cg-RX-API-DMAC7.html)
JP (2) JP4383547B2 (cg-RX-API-DMAC7.html)
KR (2) KR100564189B1 (cg-RX-API-DMAC7.html)
CN (2) CN1227025C (cg-RX-API-DMAC7.html)
AR (2) AR012010A1 (cg-RX-API-DMAC7.html)
AT (1) ATE285788T1 (cg-RX-API-DMAC7.html)
AU (2) AU740753C (cg-RX-API-DMAC7.html)
BR (2) BR9809304B1 (cg-RX-API-DMAC7.html)
CA (2) CA2287267C (cg-RX-API-DMAC7.html)
CO (2) CO4950523A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ298429B6 (cg-RX-API-DMAC7.html)
DE (1) DE69828330T2 (cg-RX-API-DMAC7.html)
DK (1) DK0875252T3 (cg-RX-API-DMAC7.html)
EA (2) EA004881B1 (cg-RX-API-DMAC7.html)
EG (1) EG23685A (cg-RX-API-DMAC7.html)
ES (1) ES2234072T3 (cg-RX-API-DMAC7.html)
HU (2) HUP0003401A3 (cg-RX-API-DMAC7.html)
ID (2) ID23172A (cg-RX-API-DMAC7.html)
IL (2) IL132325A (cg-RX-API-DMAC7.html)
IN (2) IN187157B (cg-RX-API-DMAC7.html)
MY (2) MY118591A (cg-RX-API-DMAC7.html)
NO (2) NO995134L (cg-RX-API-DMAC7.html)
NZ (2) NZ337828A (cg-RX-API-DMAC7.html)
PE (2) PE84799A1 (cg-RX-API-DMAC7.html)
PL (2) PL195090B1 (cg-RX-API-DMAC7.html)
PT (1) PT875252E (cg-RX-API-DMAC7.html)
SI (1) SI0875252T1 (cg-RX-API-DMAC7.html)
SV (2) SV1998000050A (cg-RX-API-DMAC7.html)
TR (2) TR199902529T2 (cg-RX-API-DMAC7.html)
TW (2) TW585871B (cg-RX-API-DMAC7.html)
UA (2) UA73071C2 (cg-RX-API-DMAC7.html)
WO (2) WO1998048818A1 (cg-RX-API-DMAC7.html)
ZA (2) ZA983497B (cg-RX-API-DMAC7.html)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA983497B (en) 1997-04-28 1999-10-25 Lilly Co Eli Activated protein c formulations.
US6630137B1 (en) * 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
US6815533B1 (en) 1998-07-31 2004-11-09 Eli Lilly And Company Cryogranulation of activated protein C
EP1128842B1 (en) * 1998-11-13 2006-03-15 Eli Lilly And Company Use of human protein c for the manufacture of a medicament for treating heparin-induced thrombocytopenia
WO2000030677A1 (en) * 1998-11-20 2000-06-02 Eli Lilly And Company Method of treating viral hemorrhagic fever
IL142247A0 (en) * 1998-11-23 2002-03-10 Lilly Co Eli Method of treating sickle cell disease and thalassemia
CN1329503A (zh) * 1998-12-10 2002-01-02 伊莱利利公司 治疗血小板减少性紫癜和溶血性尿毒综合征的方法
US6758938B1 (en) * 1999-08-31 2004-07-06 Micron Technology, Inc. Delivery of dissolved ozone
US7204981B2 (en) * 2000-03-28 2007-04-17 Eli Lilly And Company Methods of treating diseases with activated protein C
US7087578B2 (en) * 2000-05-24 2006-08-08 Eli Lilly And Company Formulations and methods for treating hypercoagulable states
JP4279554B2 (ja) 2001-02-19 2009-06-17 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング T細胞エピトープの識別方法および低減された免疫原性を有する分子の製造方法
US7101982B2 (en) * 2001-03-30 2006-09-05 Immunex Corporation Control of ph transitions during chromatography
EP1417055A4 (en) * 2001-07-19 2007-09-26 Dmi Biosciences Inc USE OF COPPER CHELATORS TO PREVENT THE INACTIVATION OF PROTEIN C
US20030073636A1 (en) * 2001-09-19 2003-04-17 Oklahoma Medical Research Foundation Method of treating diabetes
CA2462396A1 (en) 2001-09-19 2003-03-27 Oklahoma Medical Research Foundation Treatment of sepsis with tafi
DE10149030A1 (de) * 2001-10-05 2003-04-10 Viscum Ag Stabile galenische gefriergetrocknete Arzneimittelzubereitung von rViscumin
BR0213293A (pt) 2001-10-15 2004-12-21 Chiron Corp Uso de tfpi ou de um análogo de tfpi no tratamento de septicemia
JP2005530683A (ja) 2001-12-21 2005-10-13 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第vii因子ポリペプチドの液体組成物
CA2475738A1 (en) * 2002-03-08 2003-09-18 Eli Lilly And Company Activated protein c formulations
CN101912601B (zh) 2002-06-21 2012-08-29 诺和诺德医疗保健公司 因子vii多肽的稳定化固体组合物
JP2006504772A (ja) * 2002-10-29 2006-02-09 アルザ・コーポレーション 安定化された固体ポリペプチド粒子
US20070142272A1 (en) * 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity
US7897734B2 (en) 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
ES2382157T3 (es) * 2003-06-25 2012-06-05 Novo Nordisk Health Care Ag Composición líquida de polipépttidos del factor VII
MXPA06010587A (es) * 2004-03-17 2007-03-29 Chiron Corp Tratamiento de neumonia severa adquirida en comunidad por administracion del inhibidor de la via del factor tisular (tfpi).
JP2008507561A (ja) * 2004-07-23 2008-03-13 ザ ユニバーシティ オブ ロチェスター 活性化プロテインcによる、脳内のプラスミノゲン活性化因子の不都合な作用の阻害
EP1913155A4 (en) * 2005-06-23 2009-08-12 Univ British Columbia COAGULATION FACTOR III POLYMORPHISMS ASSOCIATED WITH PREDICTION RELATING TO THE RESULTS AND RESPONSE OF A SUBJECT TO THERAPY
EP2029740B1 (en) * 2006-05-31 2012-06-20 Genzyme Corporation Use of polysaccharides for promotion of enzymatic activity
US20100041600A1 (en) * 2006-06-09 2010-02-18 Russel James A Interferon gamma polymorphisms as indicators of subject outcome in critically ill subjects
ES2365832T3 (es) * 2007-03-05 2011-10-11 Cadila Healthcare Limited Composiciones que comprenden conjugados de peg-interferón alfa y rafinosa como crioprotector.
CA2681752A1 (en) 2007-03-29 2008-10-09 Abbott Laboratories Crystalline anti-human 1l-12 antibodies
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
US8420081B2 (en) * 2007-11-30 2013-04-16 Abbvie, Inc. Antibody formulations and methods of making same
US20110171200A1 (en) * 2008-01-15 2011-07-14 Walley Keith R Protein c rs2069915 as a response predictor to survival and administration of activated protein c or protein c-like compound
MX2011005672A (es) * 2008-11-28 2011-06-20 Abbott Lab Composiciones de anticuerpo estables y metodos para estabilizar a las mismas.
WO2012068519A2 (en) 2010-11-19 2012-05-24 Sirius Genomics Inc. Markers associated with response to activated protein c administration, and uses thereof
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
EP2834635A4 (en) 2012-04-03 2015-09-02 Smiths Medical Asd Inc COMPOSITIONS WITH A HEPARINE ACCUMULATIVE AND METHOD THEREFOR
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
JP6273272B2 (ja) 2012-07-04 2018-01-31 ジージー バイオテック エルエルシー 炎症性皮膚障害の治療
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
HK1211981A1 (en) 2012-09-02 2016-06-03 Abbvie Inc. Methods to control protein heterogeneity
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
DK3137102T3 (da) 2014-04-16 2021-10-11 Zz Biotech Llc Apc til anvendelse til behandling af unormal kutan ardannelse
ES2890623T3 (es) 2014-04-16 2022-01-20 Zz Biotech Llc Uso del análogo de APC para curar heridas
US11058750B2 (en) 2015-12-03 2021-07-13 Mor Research Applications Ltd. Compositions and methods for treatment of ocular diseases
DK3463308T4 (da) * 2016-06-01 2026-02-09 Servier Ip Uk Ltd Formuleringer af polyalkylenoxid-asparaginase og fremgangsmåder til fremstilling og anvendelse deraf
CN108159399B (zh) * 2017-12-29 2020-07-24 华中科技大学同济医学院附属同济医院 一种凝血蛋白酶aPC在防治糖尿病心肌病药物中的应用
WO2023119230A1 (en) 2021-12-22 2023-06-29 L'oreal Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US4849403A (en) * 1985-05-29 1989-07-18 Pentapharm Ag Protein C activator, methods of preparation and use thereof
US5516650A (en) 1985-06-27 1996-05-14 Zymogenetics, Inc. Production of activated protein C
AT399095B (de) * 1986-03-27 1995-03-27 Vukovich Thomas Dr Verfahren zur auftrennung von proteinen mittels gradientenelution und vorrichtung zur durchführung des verfahrens
US5175087A (en) * 1987-07-06 1992-12-29 Biopool International, Inc. Method of performing tissue plasminogen activator assay
CA1329760C (en) * 1987-10-29 1994-05-24 Ted C. K. Lee Plasma and recombinant protein formulations in high ionic strength media
US4877608A (en) * 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
US4992373A (en) * 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
JP2739050B2 (ja) * 1988-01-28 1998-04-08 ヘキスト薬品工業株式会社 抗血液凝固剤
JPH01226900A (ja) * 1988-03-08 1989-09-11 Green Cross Corp:The プロテインcの精製方法
DE3823519A1 (de) * 1988-07-12 1990-01-18 Basf Ag Verfahren zur reinigung von aktiviertem protein c
US4981952A (en) * 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
US5093117A (en) * 1989-01-24 1992-03-03 Baxter International Inc. Compositions and method for the treatment or prophylaxis of sepsis or septic shock
JPH05506354A (ja) * 1990-02-09 1993-09-22 ザイモジェネティクス,インコーポレイティド 端が切り取られた軽鎖を有する活性プロテインc
IL97312A (en) * 1990-02-23 1999-01-26 Lilly Co Eli A method of generating a polypeptide in an eukaryotic vector AND recombinant surrogate cell containing an enhanced transcriptional control unit based on the primary late adenovirus coefficient
US5040862A (en) 1990-05-07 1991-08-20 Corning Incorporated Method of trimming optical power
AT402262B (de) * 1991-06-20 1997-03-25 Immuno Ag Arzneimittel enthaltend aktiviertes protein c
US5413732A (en) * 1991-08-19 1995-05-09 Abaxis, Inc. Reagent compositions for analytical testing
MY110664A (en) 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
DE4234295A1 (de) * 1992-10-12 1994-04-14 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US5395923A (en) * 1993-02-23 1995-03-07 Haemacure-Biotech, Inc. Process for the obtention of a biological adhesive made of concentrated coagulation factors by "salting-out"
JP2886061B2 (ja) * 1993-10-29 1999-04-26 財団法人化学及血清療法研究所 プロテインcもしくは活性化プロテインcの安定化方法及び安定化組成物
JP3043558B2 (ja) * 1993-10-29 2000-05-22 財団法人化学及血清療法研究所 ヒト活性化プロテインc調製物及びその製法
JPH07165605A (ja) * 1993-12-16 1995-06-27 Teijin Ltd 活性化プロテインcバイアル
NZ270271A (en) * 1994-01-05 1996-07-26 Lilly Co Eli Minimizing protein c degradation
JPH08301786A (ja) * 1995-05-11 1996-11-19 Mochida Pharmaceut Co Ltd 吸収性骨疾患予防・治療剤
WO1997020043A1 (en) 1995-11-30 1997-06-05 Zymogenetics, Inc. Protein c production in transgenic animals
ZA983497B (en) 1997-04-28 1999-10-25 Lilly Co Eli Activated protein c formulations.
HUP0001237A3 (en) 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders

Also Published As

Publication number Publication date
NZ337828A (en) 2001-06-29
PE86299A1 (es) 1999-09-17
AU7258998A (en) 1998-11-24
CA2287267C (en) 2006-08-15
AU743531B2 (en) 2002-01-31
NO995198D0 (no) 1999-10-25
CN1235638C (zh) 2006-01-11
EP0875563A3 (en) 2000-08-02
TR199902631T2 (xx) 2000-01-21
IL132502A0 (en) 2001-03-19
WO1998048822A1 (en) 1998-11-05
SV1998000050A (es) 1999-01-13
PL195642B1 (pl) 2007-10-31
JP4383546B2 (ja) 2009-12-16
IL132325A (en) 2005-07-25
EA199900979A1 (ru) 2000-06-26
JP2001524111A (ja) 2001-11-27
EP0875252B1 (en) 2004-12-29
KR100564189B1 (ko) 2006-03-27
AU740753B2 (en) 2001-11-15
AR015598A1 (es) 2001-05-16
DE69828330D1 (de) 2005-02-03
AU7161898A (en) 1998-11-24
US6436397B1 (en) 2002-08-20
NO995134L (no) 1999-12-21
DE69828330T2 (de) 2005-10-13
HK1016472A1 (en) 1999-11-05
EG23685A (en) 2007-05-09
WO1998048818A1 (en) 1998-11-05
ZA983497B (en) 1999-10-25
KR20010020325A (ko) 2001-03-15
CN1227025C (zh) 2005-11-16
HU224826B1 (en) 2006-02-28
US6395270B1 (en) 2002-05-28
NZ500346A (en) 2001-08-31
PL195090B1 (pl) 2007-08-31
MY120984A (en) 2005-12-30
IN187157B (cg-RX-API-DMAC7.html) 2002-02-16
UA55448C2 (uk) 2003-04-15
ID22933A (id) 1999-12-16
TW585871B (en) 2004-05-01
CN1261280A (zh) 2000-07-26
KR100450856B1 (ko) 2004-10-02
JP2001527543A (ja) 2001-12-25
PT875252E (pt) 2005-03-31
HUP0100284A3 (en) 2003-08-28
CA2288143A1 (en) 1998-11-05
ATE285788T1 (de) 2005-01-15
HUP0003401A3 (en) 2003-01-28
EA004881B1 (ru) 2004-08-26
AR012010A1 (es) 2000-09-13
US6162629A (en) 2000-12-19
ZA983496B (en) 1999-10-25
UA73071C2 (en) 2005-06-15
AU740753C (en) 2002-10-10
PL336889A1 (en) 2000-07-17
BR9809292A (pt) 2000-07-04
CZ298429B6 (cs) 2007-10-03
KR20010020242A (ko) 2001-03-15
CZ381099A3 (cs) 2000-03-15
CO4950523A1 (es) 2000-09-01
TWI242443B (en) 2005-11-01
CN1254284A (zh) 2000-05-24
NO995134D0 (no) 1999-10-21
JP4383547B2 (ja) 2009-12-16
DK0875252T3 (da) 2005-04-25
IN183798B (cg-RX-API-DMAC7.html) 2000-04-15
CA2288143C (en) 2012-08-21
ES2234072T3 (es) 2005-06-16
SI0875252T1 (en) 2005-06-30
CO4940438A1 (es) 2000-07-24
TR199902529T2 (xx) 2000-02-21
PL336420A1 (en) 2000-06-19
IL132325A0 (en) 2001-03-19
EP0875563A2 (en) 1998-11-04
CA2287267A1 (en) 1998-11-05
NO995198L (no) 1999-10-25
EA002149B1 (ru) 2001-12-24
EP0875252A2 (en) 1998-11-04
MY118591A (en) 2004-12-31
HUP0100284A2 (hu) 2001-06-28
EP0875252A3 (en) 2000-07-26
ID23172A (id) 2000-03-23
US6159468A (en) 2000-12-12
BR9809304A (pt) 2000-10-17
EA199900980A1 (ru) 2000-04-24
HUP0003401A2 (hu) 2001-02-28
SV1998000051A (es) 1998-12-11
PE84799A1 (es) 1999-09-16

Similar Documents

Publication Publication Date Title
KR100450856B1 (ko) 활성 단백질 c 제제
US6630137B1 (en) Activated protein C formulations
RU2201252C2 (ru) Устойчивая, свободная от альбумина лиофилизованная композиция рекомбинантного фактора viii
FI85335B (fi) Foerfarande foer framstaellning av lyofiliserad, farmaceutisk vaevnadsplasminogenaktivator(t-pa)-komposition.
JP2002530353A (ja) ウイルス性出血熱の処置法
EP2268267B1 (en) Dry transglutaminase composition
US20050143283A1 (en) Activated protein c formulations
EP1289543A2 (en) Formulations and methods for treating hypercoagulable states
US6372213B2 (en) Method of treating sickle cell disease or thalassemia
US6743426B2 (en) Method of treating heparin-induced thrombocytopenia
EP1561469A1 (en) Activated Protein C Formulations
HK1016472B (en) Activated protein c formulations
JPH0369332B2 (cg-RX-API-DMAC7.html)
JP2002531519A (ja) 血栓性血小板減少性紫斑病および溶血性尿毒症性症候群の処置法
RU2257224C1 (ru) Способ получения концентрата плазмина человека и продукт для использования в медицине
MXPA01005038A (en) Method of treating viral hemorrhagic fever

Legal Events

Date Code Title Description
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA A CLASSIFICACAO DE A61K 31/725.

Ipc: A61K 38/46 (2007.01), A61K 38/48 (2007.01), A61K 4

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 08/02/2011, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 17A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2308 DE 31-03-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.